1 Super Growth Stock Down 63% to Buy Hand Over Fist in 2025
Leading organ transplant technology provider TransMedics (NASDAQ: TMDX) increased sales by more than 100% in 10 straight quarters from early 2022 to mid-2024. However, after delivering revenue growth of “only” 64% in its latest quarter — while lowering guidance for a 35% increase in the upcoming fourth quarter — the company has seen its stock plummet roughly 63% from its highs.
As substantial as TransMedics’ stock sell-off has been, its underlying business is by no means 63% worse. And remember, this adverse reaction primarily results from 90 to 180 days’ worth of data.
As we keep our gaze upon a decades-long time frame rather than mere days, here is why I believe TransMedics looks like a super growth stock to consider in 2025 while its stock remains discounted.
​  [#item_full_content]
